Jennings Anne Louise, Davies Andrew N, Higgins Julian P T, Anzures-Cabrera Judith, Broadley Karen E
Department of Palliative Medicine, Royal Marsden NHS Trust, London, UK.
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD002066. doi: 10.1002/14651858.CD002066.pub2.
Breathlessness is a common symptom in people with advanced disease. The most effective treatments are aimed at treating the underlying cause of the breathlessness but this may not be possible and symptomatic treatment is often necessary. Strategies for the symptomatic treatment of breathlessness have never been systematically evaluated. Opioids are commonly used to treat breathlessness: the mechanisms underlying their effectiveness are not completely clear and there have been few good-sized trials in this area.
To determine the effectiveness of opioid drugs given by any route in relieving the symptom of breathlessness in patients who are being treated palliatively.
An electronic search was carried out of Medline, Embase, CINAHL, T he Cochrane L ibrary, Dissertation Abstracts, Cancercd and SIGLE. Review articles and reference lists of retrieved articles were hand searched. Date of most recent search: May 1999.
Randomised double-blind, controlled trials comparing the use of any opioid drug against placebo for the relief of breathlessness were included. Patients with any illness suffering from breathlessness were included and the intervention was any opioid, given by any route, in any dose.
Studies identified by the search were imported into a reference manager database. The full texts of the relevant studies were retrieved and data were independently extracted by two review authors. Studies were quality scored according to the Oxford Quality scale. The primary outcome measure used was breathlessness and the secondary outcome measure was exercise tolerance. Studies were divided into non-nebulised and nebulised and were analysed both separately and together. A qualitative analysis was carried out of adverse effects of opioids. Where appropriate, meta-analysis was carried out.
Eighteen studies were identified of which nine involved the non-nebulised route of administration and nine the nebulised route. A small but statistically significant positive effect of opioids was seen on breathlessness in the analysis of studies using non-nebulised opioids. There was no statistically significant positive effect seen for exercise tolerance in either group of studies or for breathlessness in the studies using nebulised opioids.
AUTHORS' CONCLUSIONS: There is evidence to support the use of oral or parenteral opioids to palliate breathlessness although numbers of patients involved in the studies were small. No evidence was found to support the use of nebulised opioids. Further research with larger numbers of patients, using standardised protocols and with quality of life measures is needed.
呼吸困难是晚期疾病患者的常见症状。最有效的治疗方法是针对呼吸困难的根本原因进行治疗,但这可能无法实现,因此对症治疗往往是必要的。呼吸困难对症治疗的策略从未得到系统评估。阿片类药物常用于治疗呼吸困难:其有效性的潜在机制尚不完全清楚,该领域也很少有大规模试验。
确定通过任何途径给予阿片类药物对接受姑息治疗的患者缓解呼吸困难症状的有效性。
对Medline、Embase、CINAHL、Cochrane图书馆、学位论文摘要、Cancercd和SIGLE进行电子检索。对检索到的文章的综述文章和参考文献列表进行手工检索。最近一次检索日期:1999年5月。
纳入比较使用任何阿片类药物与安慰剂缓解呼吸困难的随机双盲对照试验。纳入患有任何疾病且有呼吸困难的患者,干预措施为通过任何途径、任何剂量给予任何阿片类药物。
检索到的研究被导入参考文献管理数据库。检索相关研究的全文,由两位综述作者独立提取数据。根据牛津质量量表对研究进行质量评分。主要结局指标为呼吸困难,次要结局指标为运动耐量。研究分为非雾化和雾化两组,分别进行分析和综合分析。对阿片类药物的不良反应进行定性分析。在适当情况下,进行荟萃分析。
共确定18项研究,其中9项涉及非雾化给药途径,9项涉及雾化给药途径。在使用非雾化阿片类药物的研究分析中,阿片类药物对呼吸困难有微小但具有统计学意义的积极作用。在两组研究中,运动耐量或使用雾化阿片类药物的研究中呼吸困难均未观察到具有统计学意义的积极作用。
有证据支持使用口服或胃肠外阿片类药物缓解呼吸困难,尽管参与研究的患者数量较少。未发现支持使用雾化阿片类药物的证据。需要使用标准化方案并采用生活质量测量方法,对更多患者进行进一步研究。